financetom
Business
financetom
/
Business
/
Omega Healthcare Q2 revenue misses expectations, net income rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Omega Healthcare Q2 revenue misses expectations, net income rises
Aug 1, 2025 7:38 AM

(Repeats to attach to corrected alerts, no changes to text)

Overview

* Omega Q2 net income rises to $140 mln, up from $117 mln

last

year

* Company completed $527 mln in new investments during Q2

* Revenue missed analyst expectations, per LSEG data

Outlook

* Omega raises 2025 AFFO guidance to $3.04-$3.07 per share

* Company expects Genesis to pay full rent during bankruptcy

* Omega sees favorable operating metrics and active

investment

pipeline

* Company highlights strong balance sheet for future

investments

Result Drivers

* INVESTMENTS - Completed $527 mln in new investments,

including

$502 mln in real estate acquisitions

* LEASE RESTRUCTURING - LaVie bankruptcy led to lease

restructuring, maintaining rent income

* BANKRUPTCY SUPPORT - Genesis bankruptcy supported by $8

mln DIP

financing, ensuring rent payments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $282.50 $293 mln

Revenue mln (5

Analysts

)

Q2 Net $140 mln

Income

Q2 $232 mln

Adjusted

FFO

Analyst Coverage

* The current average analyst rating on the shares is "buy"

and

the breakdown of recommendations is 7 "strong buy" or "buy", 9

"hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialized

reits

peer group is "buy"

* Wall Street's median 12-month price target for Omega

Healthcare

Investors Inc ( OHI ) is $40.00, about 2.9% above its July 30 closing

price of $38.83

* The stock recently traded at 23 times the next 12-month

earnings

vs. a P/E of 23 three months ago

Press Release:

(This story was created using Reuters automation and AI based

on LSEG and company data. It was checked and edited by a Reuters

journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China leaves benchmark rates steady as PBOC walks tight rope
China leaves benchmark rates steady as PBOC walks tight rope
Jun 19, 2024
SHANGHAI/SINGAPORE (Reuters) -China left benchmark lending rates unchanged at a monthly fixing on Thursday, in line with market expectations. WHY IT'S IMPORTANT The steady monthly LPR fixings underscore that Beijing's monetary easing efforts continued to be limited by narrowing interest rate margins and a weakening currency, despite a flurry of recent data showing more support is needed to shore up...
BRIEF-Vanda Pharmaceuticals Says Board Has Rejected Proposals; Recent Unsolicited Takeover Proposals Are Not In The Best Interests Of The Company And Its Shareholders
BRIEF-Vanda Pharmaceuticals Says Board Has Rejected Proposals; Recent Unsolicited Takeover Proposals Are Not In The Best Interests Of The Company And Its Shareholders
Jun 19, 2024
June 19 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ): * VANDA PHARMACEUTICALS BOARD OF DIRECTORS DETERMINES THAT RECENT UNSOLICITED TAKEOVER PROPOSALS ARE NOT IN THE BEST INTERESTS OF THE COMPANY AND ITS SHAREHOLDERS * BOARD HAS REJECTED PROPOSALS * PROPOSAL FROM CYCLE GROUP AND REVISED PROPOSAL FROM FUTURE PAK UNDERVALUE VANDA Source text for Eikon: Further company coverage: ...
Hong Kong's FWD to raise $600 mln in 7-yr subordinated dollar bond, term sheet shows
Hong Kong's FWD to raise $600 mln in 7-yr subordinated dollar bond, term sheet shows
Jun 19, 2024
SYDNEY, June 20 (Reuters) - Hong Kong-based insurer FWD Group is raising $600 million from the sale of a 7-year subordinated dollar bond, according to a term sheet seen by Reuters on Thursday. The initial price guidance given to investors is Treasuries plus 380 basis points, the term sheet said. FWD said in an exchange filing the proceeds would be...
Vanda rejects Future Pak and Cycle Pharma's takeover offers
Vanda rejects Future Pak and Cycle Pharma's takeover offers
Jun 19, 2024
June 19 (Reuters) - Vanda Pharmaceuticals ( VNDA ) said on Wednesday that it has rejected takeover offers UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers undervalue the U.S. drugmaker. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved